Latest news with #RichardChen
Yahoo
4 days ago
- Business
- Yahoo
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
FREMONT, Calif., June 02, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple negative breast cancer (TNBC), one of the most aggressive types of breast cancer. "Many triple negative breast cancer patients receive neoadjuvant therapy prior to surgery as standard of care. The data from these two studies independently suggest that an ultrasensitive ctDNA assay like NeXT Personal could help these patients better understand their risk of relapse, with the potential to help inform the need for additional therapy," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "We believe this data, once published, can form the basis for seeking reimbursement coverage for neoadjuvant therapy monitoring in breast cancer. We are excited to continue to work with leading collaborators to expand the data around the use of NeXT Personal in breast cancer with the goal of helping breast cancer patients optimize their care." Results from the PREDICT DNA study were presented yesterday by Dr. Natasha Hunter, MD, University of Washington, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT DNA trial)." "The PREDICT DNA study prospectively evaluated ctDNA in early-stage patients with HER2-positive and triple negative breast cancer. The trial was initiated a decade ago and accrued 228 patients across 22 sites in the United States, and was statistically designed and powered for analysis of ctDNA to predict for pathologic complete response (pCR), and whether ctDNA could be a prognostic test to identify patients at high vs. very low risk for recurrence," said Dr. Ben Park, MD PhD, Vanderbilt-Ingram Cancer Center. "We partnered with Personalis because of their technology's ultrasensitive detection of ctDNA down to 1 to 3 parts per million. Our results demonstrate that patients who 'clear' their ctDNA after upfront chemotherapy have excellent outcomes that mirror those with pCR, identifying a group of patients who, despite having residual disease at the time of surgery, will be at extremely low risk for recurrence. Conversely, those with detectable ctDNA after upfront chemotherapy are at a much higher risk of recurrence, and serial ctDNA measurements after surgery can help identify patients who may benefit from either escalation or de-escalation of therapies. We are truly excited by these results as they will allow us to more precisely risk-stratify patients with breast cancer in future trials and clinical practice." Key findings included: ctDNA status after completion of NAT (post-NAT) was highly prognostic for relapse-free survival (RFS). Patients with ctDNA detected post-NAT were ~10 times more likely to relapse than patients who were ctDNA negative. Detection of ctDNA post-NAT was more predictive of recurrence than pCR. Patients who did not have detectable post-NAT ctDNA had excellent outcomes regardless of pathologic response. Preliminary analyses indicate that patients who had post-surgical ctDNA detected were >85 times more likely to experience disease recurrence. 48% of post-NAT ctDNA detections were <100 PPM, highlighting the importance of NeXT Personal's ultrasensitive performance. Overall, the results suggest that ultrasensitive ctDNA detection in patients with TNBC after completion of NAT and prior to surgery may be used as a prognostic marker, independent of pCR, to guide clinical decision making for additional adjuvant therapies. Dr. Luc Cabel, MD, PhD, Institut Curie, Paris, presented results from a second study titled "Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC)." This study included 86 patients with early stage (Stage I-III) TNBC receiving neoadjuvant therapy. Key findings included: ctDNA was detected in 100% (84/84) of pretreatment baseline plasma samples. The majority of ctDNA detections during NAT (51%) and post-NAT (55%) were in the ultrasensitive range below 100 PPM of ctDNA. Post-NAT ctDNA status was highly prognostic. Patients with ctDNA detected post-NAT were ~36 times more likely to have a distant relapse than patients who tested negative. For patients who were non-pCR, ctDNA negative patients were 93% less likely to relapse than ctDNA positive patients. ctDNA status can be combined with pCR status to assess patient distant relapse risk following NAT. Said François-Clément Bidard, MD, PhD, one of the Institut Curie lead investigators on the study, "Our results uncover the clinical need for ultrasensitive MRD testing, and pave the way for ctDNA-based adjuvant therapy decisions in early triple negative breast cancer." About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO. View source version on Contacts Investors: Caroline Cornerinvestors@ 415-202-5678 Media Contact pr@
Business Wire
4 days ago
- Health
- Business Wire
New Data Shows NeXT Personal ® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple negative breast cancer (TNBC), one of the most aggressive types of breast cancer. 'Many triple negative breast cancer patients receive neoadjuvant therapy prior to surgery as standard of care. The data from these two studies independently suggest that an ultrasensitive ctDNA assay like NeXT Personal could help these patients better understand their risk of relapse, with the potential to help inform the need for additional therapy,' said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. 'We believe this data, once published, can form the basis for seeking reimbursement coverage for neoadjuvant therapy monitoring in breast cancer. We are excited to continue to work with leading collaborators to expand the data around the use of NeXT Personal in breast cancer with the goal of helping breast cancer patients optimize their care.' Results from the PREDICT DNA study were presented yesterday by Dr. Natasha Hunter, MD, University of Washington, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled 'Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT DNA trial).' 'The PREDICT DNA study prospectively evaluated ctDNA in early-stage patients with HER2-positive and triple negative breast cancer. The trial was initiated a decade ago and accrued 228 patients across 22 sites in the United States, and was statistically designed and powered for analysis of ctDNA to predict for pathologic complete response (pCR), and whether ctDNA could be a prognostic test to identify patients at high vs. very low risk for recurrence,' said Dr. Ben Park, MD PhD, Vanderbilt-Ingram Cancer Center. 'We partnered with Personalis because of their technology's ultrasensitive detection of ctDNA down to 1 to 3 parts per million. Our results demonstrate that patients who 'clear' their ctDNA after upfront chemotherapy have excellent outcomes that mirror those with pCR, identifying a group of patients who, despite having residual disease at the time of surgery, will be at extremely low risk for recurrence. Conversely, those with detectable ctDNA after upfront chemotherapy are at a much higher risk of recurrence, and serial ctDNA measurements after surgery can help identify patients who may benefit from either escalation or de-escalation of therapies. We are truly excited by these results as they will allow us to more precisely risk-stratify patients with breast cancer in future trials and clinical practice.' Key findings included: ctDNA status after completion of NAT (post-NAT) was highly prognostic for relapse-free survival (RFS). Patients with ctDNA detected post-NAT were ~10 times more likely to relapse than patients who were ctDNA negative. Detection of ctDNA post-NAT was more predictive of recurrence than pCR. Patients who did not have detectable post-NAT ctDNA had excellent outcomes regardless of pathologic response. Preliminary analyses indicate that patients who had post-surgical ctDNA detected were >85 times more likely to experience disease recurrence. 48% of post-NAT ctDNA detections were <100 PPM, highlighting the importance of NeXT Personal's ultrasensitive performance. Overall, the results suggest that ultrasensitive ctDNA detection in patients with TNBC after completion of NAT and prior to surgery may be used as a prognostic marker, independent of pCR, to guide clinical decision making for additional adjuvant therapies. Dr. Luc Cabel, MD, PhD, Institut Curie, Paris, presented results from a second study titled 'Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC).' This study included 86 patients with early stage (Stage I-III) TNBC receiving neoadjuvant therapy. Key findings included: ctDNA was detected in 100% (84/84) of pretreatment baseline plasma samples. The majority of ctDNA detections during NAT (51%) and post-NAT (55%) were in the ultrasensitive range below 100 PPM of ctDNA. Post-NAT ctDNA status was highly prognostic. Patients with ctDNA detected post-NAT were ~36 times more likely to have a distant relapse than patients who tested negative. For patients who were non-pCR, ctDNA negative patients were 93% less likely to relapse than ctDNA positive patients. ctDNA status can be combined with pCR status to assess patient distant relapse risk following NAT. Said François-Clément Bidard, MD, PhD, one of the Institut Curie lead investigators on the study, 'Our results uncover the clinical need for ultrasensitive MRD testing, and pave the way for ctDNA-based adjuvant therapy decisions in early triple negative breast cancer.' About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are 'forward-looking statements' within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO.
Business Wire
22-05-2025
- Health
- Business Wire
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal ® ultrasensitive ctDNA assay for residual and recurrent cancer detection. 'These studies continue to expand the clinical data for NeXT Personal into new areas, including neoadjuvant treatment in breast cancer and cervical cancer,' said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis. 'We continue to be driven by our mission to provide physicians and their patients better tools for guiding treatment through earlier, more sensitive, and more accurate detection of residual and recurrent cancer.' The presentations are as follows (all times CDT): Clinical Science Symposium: Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial) Session: Breast Cancer Time: Location: Arie Crown Theater/Live Stream Presenter: Natasha Hunter, MD, University of Washington Oral Presentation: Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses Session: Gynecologic Cancer Time: June 2, 2025, 8:48 AM - 9:00 AM Location: Room S100a (Grand Ballroom) - McCormick Place South (Level 1)/Live Stream Presenter: Jyoti Mayadev, MD, University of California San Diego Medical Center Poster Presentation: Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC) Session: Breast Cancer—Local/Regional/Adjuvant Time: June 2, 2025, 9:00 AM - 12:00 PM Location: Hall A, poster bd 145 - McCormick Place South (Level 1) Presenter: Luc Cabel, MD, PhD, Institut Curie, Paris, France Poster Presentation: Ultrasensitive ctDNA monitoring to reveal early predictors of immunotherapy success in advanced cancer Session: Developmental Therapeutics—Immunotherapy Time: June 2, 2025, 1:30 PM - 4:30 PM Location: Hall A, poster bd 208 - McCormick Place South (Level 1) Presenter: Charles Abbott, PhD, Personalis, Inc., Fremont, CA About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are 'forward-looking statements' within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect residual and recurrent cancer earlier, more sensitively, and more accurately, guide treatment, monitor a patient's response to therapy, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the presentations and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO.
TECHx
16-05-2025
- Business
- TECHx
Cathay Adopts AI-Powered Automation with UiPath
Home » Smart Sectors » Travel & Hospitality » Cathay Adopts AI-Powered Automation with UiPath UiPath (NYSE: PATH), a leading enterprise automation and AI software company, announced a key collaboration with Cathay, the Hong Kong-based premium travel lifestyle brand. The goal is to drive positive change through AI-powered automation. UiPath revealed that Cathay is strengthening its position as a digital leader by improving customer experience, safety, operational efficiency, productivity, and compliance. This progress was recognized at UiPath FORWARD, the company's global AI and automation event in Las Vegas. At the event, Cathay was named a UiPath AI25 Award Winner. The annual program honors 25 companies that use AI and automation to enable strategic change and deliver bold outcomes. Aldric Chau, General Manager Digital at Cathay, expressed pride in the recognition. He reported that the company's investment in AI and automation has led to strong results. He added that Cathay will continue to innovate with UiPath to unlock the full potential of automation, AI, and generative AI. Richard Chen, Regional Vice President, Greater China at UiPath, stated that AI-powered automation helps streamline workflows, boost accuracy, and drive cost savings. He highlighted its importance for the aviation sector as global travel rebounds after the pandemic. Cathay began using the UiPath Platform in 2018. Today, it operates more than 160 bots across 20 departments. These bots assist employees with routine tasks, allowing them to focus on higher-value work. • Cathay uses UiPath Action Center, AI Center, and Document Understanding tools. • Over 72% of SAMEA region invoices are processed automatically, reducing time by fourfold. Cathay also automated its flight re-seat notification process. This task is now 20 times faster than the manual method. In back-office operations, automation cut tax declaration prep from three weeks to just two days. Automated flight schedule reporting also cut time by 50% while improving compliance. The company introduced its first Intelligent Document Processing (IDP) use case to handle invoices. This has improved speed and allowed teams to focus on strategic tasks like vendor engagement. UiPath reported that these efforts are helping Cathay turn AI potential into measurable business outcomes. Looking ahead, Cathay plans to explore new areas with UiPath, such as process mining and further IDP use cases. This continued collaboration aims to empower staff and advance Cathay's digital transformation journey through AI-powered automation.
Techday NZ
16-05-2025
- Business
- Techday NZ
Cathay boosts efficiency with expanded automation & AI tools
Cathay is utilising enterprise automation and artificial intelligence from UiPath to improve operational efficiency, reduce manual work, and enhance the travel experience for both passengers and staff. In response to an increase in air travel demand, Cathay is updating its operations by deploying automation technology across various business functions, including customer service and flight operations. The company has implemented UiPath's automation solutions in over 20 departments, leveraging more than 160 bots to support daily employee activities. Cathay's digital initiatives have been recognised with the UiPath AI25 Award, which honours customers using a combination of AI and automation to drive significant organisational outcomes. The award identifies 25 companies globally for their strategic application of these technologies. Aldric Chau, General Manager Digital, Cathay, said, "We are honoured to be an AI25 Award Winner and are pleased to witness that our investment in AI and automation has turned into fruitful results." "We continue to innovate through our close collaboration with UiPath to harness the full power of automation, AI and generative AI to ultimately deliver significant outcomes for our customers and to our internal operations. By leveraging AI and automation, we aim to maintain our digital leadership by prioritising a strong customer-centric approach and continuously pursuing innovation." Richard Chen, Regional Vice President, Greater China at UiPath, commented, "AI-powered automation can help organisations streamline workflows and drive efficiencies, which has huge benefits such as enhanced customer and employee experiences, substantial cost savings, improved accuracy, and increased productivity to drive greater business value." "It is particularly important for the aviation sector that needs to significantly scale up in order to satisfy the huge demand as travel resurges after the pandemic. We are proud to enable the digital transformation journey at Cathay and look forward to working closely together to continue delivering the strongest outcomes for its employees and customers." Cathay began adopting the UiPath Platform in 2018 and now deploys advanced UiPath tools, including Action Centre, AI Centre, and Document Understanding to automate manual and repetitive tasks. These initiatives form part of Cathay's broader digital transformation strategy as the airline rebuilds operations post-pandemic, aiming to redirect employee focus onto higher-value activities. UiPath's AI and automation have played a key role in managing high-volume, high-intensity processes within Cathay's business units. Through UiPath Document Understanding, the company has reduced the time required for document processing, improving accuracy and handling a larger volume of processes. Cathay uses automation to streamline its flight re-seat notification process for passengers, with bots enabling the task to be completed around 20 times faster than previous manual email notification methods. Automation has also improved back-office operations; for instance, the preparation of tax declarations, which once took approximately three weeks, can now be completed in one to two days using automated systems. UiPath automation has helped Cathay strengthen compliance, particularly in flight scheduling, where automated reporting has cut reporting time by 50% and reduced human error. The airline has also introduced Intelligent Document Processing (IDP) for invoice handling in the SAMEA region. Currently, more than 72% of these invoices are processed automatically, reducing overall processing time by a factor of four and freeing staff for more strategic tasks such as managing vendor relationships. The collaboration between Cathay and UiPath includes exploration into future opportunities in intelligent document processing and process mining. The airline intends to continue this partnership to empower staff and advance its organisational capabilities as the company adapts to ongoing digital change.
